Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.

The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks--either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV--expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the feasibility of future HIV prevention trial designs have intensified. This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population.

[1]  M. Dybul,et al.  The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review , 2013, Current opinion in HIV and AIDS.

[2]  D. Wassenaar,et al.  Improving understanding of clinical trial procedures among low literacy populations: an intervention within a microbicide trial in Malawi , 2012, BMC medical ethics.

[3]  Peter L. Anderson,et al.  Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men , 2012, Science Translational Medicine.

[4]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[5]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[6]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[7]  J. Kaldor,et al.  How Good Is “Good Enough”? The Case for Varying Standards of Evidence According to Need for New Interventions in HIV Prevention , 2012, The American journal of bioethics : AJOB.

[8]  L. van Damme,et al.  Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention , 2012, AIDS.

[9]  S. Karim,et al.  Antiretroviral prophylaxis: a defining moment in HIV control , 2011, The Lancet.

[10]  Lei Wang,et al.  Prevention of HIV-1 infection with early antiretroviral therapy. , 2011, The New England journal of medicine.

[11]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[12]  C. Hankins,et al.  The challenge of defining standards of prevention in HIV prevention trials , 2010, Journal of Medical Ethics.

[13]  J. Sugarman,et al.  Developing ethics guidance for HIV prevention research: the HIV Prevention Trials Network approach , 2010, Journal of Medical Ethics.

[14]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[15]  S. Buchbinder,et al.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine , 2010, Current opinion in HIV and AIDS.

[16]  J. V. Delden,et al.  What is the Best Standard for the Standard of Care in Clinical Research , 2009 .

[17]  H. Richardson.  Gradations of researchers' obligation to provide ancillary care for HIV/AIDS in developing countries. , 2007, American journal of public health.

[18]  S. Lees,et al.  The benefits of participatory methodologies to develop effective community dialogue in the context of a microbicide trial feasibility study in Mwanza, Tanzania , 2007, BMC public health.

[19]  Stephen Moses,et al.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial , 2007, The Lancet.

[20]  Oliver Laeyendecker,et al.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial , 2007, The Lancet.

[21]  C. Weijer,et al.  Fiduciary Obligation in Clinical Research , 2006, Journal of Law, Medicine & Ethics.

[22]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[23]  S. R. Benatar,et al.  HIV prevention research and global inequality: steps towards improved standards of care* , 2005, Journal of Medical Ethics.

[24]  H. Richardson,et al.  Medical researchers' ancillary clinical care responsibilities , 2004, BMJ : British Medical Journal.

[25]  C. Slack,et al.  HIV prevention responsibilities in HIV vaccine trials: complexities facing South African researchers. , 2010, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.